KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Assets (2016 - 2025)

Novavax has reported Assets over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Assets at $1.2 billion for Q4 2025, down 24.6% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (down 24.6% YoY), and the annual figure for FY2025 was $1.2 billion, down 24.6%.
  • Assets for Q4 2025 was $1.2 billion at Novavax, roughly flat from $1.2 billion in the prior quarter.
  • Over the last five years, Assets for NVAX hit a ceiling of $2.8 billion in Q1 2022 and a floor of $1.2 billion in Q4 2025.
  • Median Assets over the past 5 years was $1.8 billion (2023), compared with a mean of $1.9 billion.
  • Biggest five-year swings in Assets: surged 695.07% in 2021 and later crashed 45.58% in 2023.
  • Novavax's Assets stood at $2.6 billion in 2021, then fell by 12.34% to $2.3 billion in 2022, then fell by 20.42% to $1.8 billion in 2023, then dropped by 13.19% to $1.6 billion in 2024, then dropped by 24.6% to $1.2 billion in 2025.
  • The last three reported values for Assets were $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.